The average one-year price target for TransMedics Group (BIT:1TMDX) has been increased to €141.32 per share, marking a 14.04% rise from the previous estimate of €123.92 dated February 23, 2026. This new target reflects an average based on various analysts, with projections ranging from €112.80 to €171.39 per share and an increase of 65.13% from the last reported closing price of €85.58.
Currently, there are 438 funds reporting positions in TransMedics, a decrease of 39.08% (281 funds) in the last quarter. Total shares owned by institutions have fallen by 21.24% over the past three months, totaling 37,125K shares. Noteworthy institutional changes include Ubs Asset Management Americas reducing its stake to 997K shares (2.91% ownership), while Goldman Sachs Group increased its holdings to 966K shares (2.82% ownership), reflecting a 27.16% gain from the prior quarter.
